Sanofi-Aventis has a robust pipeline with over 125 drugs in development; 25 of these drugs are set to launch in the next 2 to four years which will provide a substantial boost to earnings.
Sanofi-Aventis' strong global franchise will allow it to take full advantage of key demographic shifts such as aging populations in developed nations and the rising middle class in emerging markets.